Vol. 19/No. 16 | OncologyLive

Potency of CAR T-Cell Therapy Investigated in Relapsed/Refractory MCL

August 22, 2018

Axicabtagene ciloleucel (axi-cel; Yescarta) is being evaluated in patients with relapsed or refractory mantle cell lymphoma—a rare B-cell non-Hodgkin lymphoma that contributes 4200 new patients in the United States each year.

Expanded Scalp Cooling Approval Offers Patients More Choices

August 20, 2018

An expanded indication for the Paxman Scalp Cooling System to include the prevention of chemotherapy-related alopecia in patients with solid tumors will increase the population eligible for the therapy dramatically and allow for more personalized treatment options.

Experts Delve Into 4 Phenotypes of Advanced Prostate Cancer

August 20, 2018

A panel of experts during an OncLive PeerExchange® provided practical definitions for biochemical recurrent hormone-naïve nonmetastatic, metastatic hormone-naïve advancing, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer.

Neoadjuvant Immunotherapy Emerges as a New Frontier

August 20, 2018

Although checkpoint blocking immunotherapy has significantly improved outcomes for patients with advanced and metastatic disease, researchers believe the modality also may be effective in the neoadjuvant setting.

CMS Decision Helps Unlock the Potential of Next-Generation Testing

August 17, 2018

Provisions to a final national coverage determination that expanded coverage for next-generation sequencing tests have implications for any NGS-based cancer test provided to Medicare beneficiaries and will inevitably influence the coverage thinking of commercial payers.

New Recommendations Improve Accuracy of HER2 Status Designation

August 17, 2018

The guidelines for establishing HER2 status for patients with breast cancer with unclear results on initial testing have been finetuned in an update that the American Society of Clinical Oncology and the College of American Pathologists recently issued.